1stOncology™: Cancer Intelligence Service – Page 10130 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock

On February 11, 2021 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, reported that it has commenced an underwritten public offering of shares of its common stock (Press release, Corvus Pharmaceuticals, FEB 11, 2021, View Source [SID1234576180]). All of the shares to be sold in the offering will be offered by Corvus. In addition, Corvus expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in the offering at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Corvus currently expects to use the net proceeds from this offering to fund its Phase 3 clinical trial of CPI-006 and development of its other product candidates, with any remaining proceeds for working capital and general corporate purposes.

Cantor Fitzgerald & Co. and H.C. Wainwright & Co. are acting as joint book-running managers for the offering.

A shelf registration statement on Form S-3 relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission on March 19, 2020. The offering of these securities is being made only by means of a prospectus forming a part of the effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC on February 11, 2021 and is available on the SEC’s website at www.sec.gov. A copy of the preliminary prospectus supplement and accompanying prospectus relating to the offering may be obtained from: Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 6TH Floor, New York, NY 10022 or by email at [email protected] or H.C. Wainwright & Co., LLC, 430 Park Avenue, 3RD Floor, New York, NY 10022, by telephone at (646) 975-6996 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

Entry Into a Material Definitive Agreement

On February 11, 2021, Applied Therapeutics, Inc. (the "Company") reported that it entered into an underwriting agreement (the "Underwriting Agreement") with Goldman Sachs & Co. LLC, Cowen and Company, LLC and UBS Securities LLC as representatives (the "Representatives") of the several underwriters named therein (the "Underwriters"), relating to the issuance and sale pursuant to an underwritten public offering (the "Offering") of an aggregate of 3,000,000 shares (the "Shares") of its common stock, par value $0.0001 per share (the "Common Stock"), and up to 450,000 additional shares of Common Stock at the Underwriters’ option (Filing, 8-K, Applied Therapeutics, FEB 11, 2021, View Source [SID1234575200]). The Shares were sold at a public offering price of $23.00 per share, less underwriting discounts and commissions, as described in the prospectus supplement, dated February 11, 2021, filed with the Securities and Exchange Commission (the "Commission") on February 12, 2021. The offering of Common Stock closed on February 17, 2021.

Artios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients

On February 11, 2021 Artios Pharma Limited ("Artios"), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, reported the start of a clinical trial of its small-molecule ATR inhibitor, ART0380, in patients with advanced or metastatic solid tumors (Press release, Artios Pharma, FEB 11, 2021, View Source [SID1234575054]). ART0380 was originally in-licensed from The University of Texas MD Anderson Cancer Center and ShangPharma Innovation in 2019. The molecule was jointly developed as part of a collaboration between ShangPharma and MD Anderson’s Therapeutics Discovery Division.

The clinical trial of the ATR (Ataxia telangiectasia and Rad3-related kinase) inhibitor is an open-label, multi-center, Phase I/IIa study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART0380 as a monotherapy and in combination with gemcitabine in patients with advanced or metastatic solid cancers. The study will enroll up to 180 patients and will be conducted at multiple oncology centers across the USA, UK, and Europe. Full details can be found at www.clinicaltrials.gov under the identifier NCT04657068.

Niall Martin, Chief Executive Officer at Artios Pharma, said: "Our vision is to build on the success of PARP inhibition to enable more patients to benefit from DDR targeting medicines. By using insights gained from our longstanding experience in this field, we believe that our approach will address the challenges of resistance to targeted therapy, identify patients with sensitive cancers, and optimize the therapeutic index. We have done extensive preclinical work to characterise and differentiate our lead candidates and will have two programs, ART0380 and ART4215, a first in class Pol theta inhibitor, in the clinic by end of 2021. Following the recent strategic collaboration with Merck KGaA, Darmstadt, Germany, taking ART0380 into the clinic is another major milestone for Artios in the development of next generation DNA Damage Response treatments for hard-to-treat cancers."

Melissa Johnson, MD, Program Director, Lung Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology, Principal Investigator for the trial, said: "We have a strong heritage in developing novel cancer therapies. We see DDR as an exciting and promising area of research and are excited to collaborate with Artios on this important clinical trial."

ART0380 is a new investigational medicinal product that is a potent and selective inhibitor of ATR. ATR is an important signalling protein in the cellular DNA damage response to replication stress and DNA double-strand breaks that occur as cells multiply.

ART0380 is being developed as an oral anti-cancer agent for the treatment of patients with cancers harbouring defects in DNA repair and in combination with agents including established and novel agents that cause DNA damage and/or suppress a cancer’s ability to repair DNA damage.

Theratechnologies To Announce Financial Results For Fourth Quarter And Fiscal Year 2020

On February 11, 2021 Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies reported that it will issue its financial results for the fourth quarter and fiscal year ended November 30, 2020 on Thursday, February 25, 2021 (Press release, Theratechnologies, FEB 11, 2021, View Source [SID1234574992]).

A conference call will be held on February 25, 2021 at 8:30 a.m. (ET) to discuss the results. The call will be hosted by Paul Lévesque, President and Chief Executive Officer. The conference call will be open to questions from financial analysts. Media and other interested individuals are invited to participate in the call on a "listen-only" basis.

The conference call can be accessed by dialing 1-844-400-1697 (toll free) or 1-703-736-7400 (International). The conference call will also be accessible via webcast at View Source Audio replay of the conference call will be available on the same day starting at 12:00 p.m. (ET) until March 04, 2021, by dialing 1-855-859-2056 (North America) or 1-404-537-3406 (International) and by entering the access code: 8274898. The audio replay is also available until February 25, 2022 on View Source

Full-year 2020 results

On February 11, 2021 AstraZeneca reported strong results in the year, in line with guidance that was reconfirmed during the year (Press release, AstraZeneca, FEB 11, 2021, View Source [SID1234574970]). With over half of Total Revenue coming from the fast-growing new medicines1, the Company leveraged its revenue growth to make further progress in profitability, while the strategy of sustainable growth through innovation brought numerous further benefits for patients. AstraZeneca’s patient-centric strategy, focus on innovation and capital-allocation priorities remain unchanged, with sustainable long-term growth in revenue, profit and cash generation set to continue.

Pascal Soriot, Chief Executive Officer, commented: "The performance last year marked a significant step forward for AstraZeneca. Despite the significant impact from the pandemic, we delivered double-digit revenue growth to leverage improved profitability and cash generation. The consistent achievements in the pipeline, the accelerating performance of our business and the progress of the COVID-19 vaccine demonstrated what we can achieve, while the proposed acquisition of Alexion is intended to accelerate our scientific and commercial evolution even further.

Additional investment in new medicines continued to fuel our rapidly growing oncology and biopharmaceuticals therapy areas. Tagrisso’s future was enhanced with its first regulatory approval in early, potentially-curable lung cancer and further national reimbursement in China in advanced disease. Farxiga again expanded its potential beyond diabetes, while tezepelumab promised real hope for patients suffering from severe asthma. Thanks to the focus on an industry-leading pipeline and consistent execution, I am confident that we will continue to deliver more progress for patients and sustained, compelling results."